INDIANAPOLIS (Inside INdiana Business) — Indianapolis-based Eli Lilly and Co. is reporting positive results from two Phase 3 clinical trials of a drug designed to help people with type 2 diabetes. Lilly says tirzepatide led to “significant A1C and body weight reductions” in adults with the disease during the trials.
Lilly Diabetes President Mike Mason says the treatment continued to achieve “consistent efficacy and safety results” in adults with type 2 diabetes, regardless of how long they have had the disease.
“Significantly lowering A1C levels and weight are high priorities throughout the type 2 diabetes treatment journey, and the results we have seen from three SURPASS studies to date fuel our belief in tirzepatide’s ability to meet those needs,” said Mason.
Lilly says the complete data from both trials have not yet been evaluated. However, the company plans to present the data at the American Diabetes Association’s Scientific Session meeting in June, and also publish it in a peer-reviewed publication later this year.
You can learn more about the clinical trials from Lilly by clicking here.